Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.65
Bid: 0.60
Ask: 0.70
Change: 0.00 (0.00%)
Spread: 0.10 (16.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.65
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re-appointment to the Scientific Advisory Board

1 Dec 2014 07:00

RNS Number : 3368Y
Provexis PLC
01 December 2014
 



1 December 2014

 

Provexis plc

 

Re-appointment of Professor Asim Duttaroy to the Scientific Advisory Board

 

Provexis plc ('Provexis' or the 'Company'), the business that develops and licenses the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is pleased to announce the re-appointment of Professor Asim Duttaroy to the Company's Scientific Advisory Board.

 

Professor Duttaroy was the original inventor of Fruitflow® and he previously served on the Company's Scientific Advisory Board from 2003 to 2011.

 

Professor Duttaroy is a globally recognised expert in the field of nutrition studies; he is currently Group Leader of Chronic Disease at the University of Oslo's Faculty of Medicine, and on 5 November 2014 he was appointed as editor in chief of the international peer reviewed journal Food & Nutrition Research.

 

The Company's Scientific Advisory Board (SAB) is now composed of Professor Asim Duttaroy, the inventor of Fruitflow®, and Dr Niamh O'Kennedy, a research chemist specialising in the field of natural products chemistry. Dr O'Kennedy played a key role in the development of Fruitflow® and the health claim for Fruitflow® which was adopted by the European Food Safety Authority ('EFSA'). The Company's agreements with SAB members include certain confidentiality, non-compete, IP assignment and first right of view provisions.

 

On 18 November 2014 the Company announced it had signed a collaboration agreement with the University of Oslo to undertake further research into the relationship between Fruitflow® and blood pressure regulation, with collaboration work to be led by Professor Duttaroy and Dr O'Kennedy. The company is ideally positioned to develop technologies designed to extend the existing 'healthy blood flow' product claims of Fruitflow®, on a carefully managed and costed basis, with the collaboration expected to be an important step in maximising the opportunities available to commercialise the product.

 

The Company also announced on 18 November 2014 that Professor Duttaroy and Dr O'Kennedy had been granted certain new options over Ordinary Shares under the Provexis 2005 share option scheme, which the Company believes will closely align their interests with those of shareholders.

 

Dawson Buck, Chairman of Provexis, commented:

"We are delighted that Professor Duttaroy has re-joined the Scientific Advisory Board, further strengthening his longstanding relationship with the Company and its key heart-health functional food ingredient, Fruitflow.

 

We believe that Professor Duttaroy will play an important role in maximising the opportunities available to commercialise Fruitflow, to the benefit of shareholder value."

 

 

- ends -

 

For further information please contact:

 

Provexis plc Tel: 07917 670260

Dawson Buck, Chairman enquiries@provexis.com

Ian Ford, Finance Director

 

Cenkos Securities plc Tel: 020 7397 8900

Bobbie Hilliam

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAAFPALPLFFF
Date   Source Headline
10th Sep 20197:00 amRNSFinal Results
2nd Aug 20197:00 amRNSCollaboration agreement with By-Health Co., Ltd.
31st Jul 20197:00 amRNSTrading Update
27th Jun 20193:11 pmRNSTiming of trading update
12th Apr 20197:00 amRNSBoard changes
8th Mar 20199:44 amRNSHolding(s) in Company
31st Dec 20187:00 amRNSHalf-year Report
1st Nov 20181:00 pmRNSChange of Adviser and AIM Rule 17 notice
25th Oct 20181:55 pmRNSResult of AGM
16th Oct 20187:00 amRNSHolding(s) in Company
9th Oct 20184:25 pmRNSHolding(s) in Company
27th Sep 20187:10 amRNSFinal Results
27th Sep 20187:00 amRNSResults of Placing
4th Jul 20187:00 amRNSDirectorate Change - Frédéric Boned
25th Jun 20187:00 amRNSFruitflow®+ Omega-3 launch in Holland & Barrett
5th Feb 20182:16 pmRNSHolding(s) in Company
31st Jan 20188:21 amRNSDirectorate Change - Krijn Rietveld
2nd Jan 20187:00 amRNSGrant of Share Options
29th Dec 20177:09 amRNSHalf-year Report
4th Dec 20177:00 amRNSPatent application - Fruitflow and air pollution
10th Nov 20174:40 pmRNSSecond Price Monitoring Extn
10th Nov 20174:35 pmRNSPrice Monitoring Extension
2nd Nov 20174:41 pmRNSSecond Price Monitoring Extn
2nd Nov 20174:35 pmRNSPrice Monitoring Extension
31st Oct 20174:40 pmRNSSecond Price Monitoring Extn
31st Oct 20174:35 pmRNSPrice Monitoring Extension
3rd Oct 20174:10 pmRNSResult of AGM
26th Sep 20172:44 pmRNSStudy Publication
7th Sep 20177:00 amRNSPreliminary Results
4th Aug 20178:00 amRNSHolding(s) in Company
31st Jul 20177:59 amRNSResults of placing
28th Jul 20174:30 pmRNSFunding Update
3rd Jul 20177:00 amRNSFunding Update
9th Jun 20174:35 pmRNSPrice Monitoring Extension
5th Jun 20174:40 pmRNSSecond Price Monitoring Extn
5th Jun 20174:35 pmRNSPrice Monitoring Extension
19th May 20174:40 pmRNSSecond Price Monitoring Extn
19th May 20174:35 pmRNSPrice Monitoring Extension
10th May 20177:01 amRNSTrading Update
10th May 20177:00 amRNSResults of Placing
2nd May 20177:15 amRNSFunding Update
11th Apr 20174:40 pmRNSSecond Price Monitoring Extn
11th Apr 20174:35 pmRNSPrice Monitoring Extension
6th Apr 20177:00 amRNSBy-Health MOU and product launch for Fruitflow
8th Feb 20174:40 pmRNSSecond Price Monitoring Extn
8th Feb 20174:35 pmRNSPrice Monitoring Extension
30th Dec 20167:00 amRNSHalf-year Report
21st Dec 20164:41 pmRNSSecond Price Monitoring Extn
21st Dec 20164:35 pmRNSPrice Monitoring Extension
20th Dec 20167:00 amRNSFruitflow and Blood Pressure - second stage update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.